Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium

Reuters

2025/06/28

Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium

Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest $(EOI)$ from AstraZeneca plc, indicating their intent to join the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043988) on June 27, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2546724057"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546724057\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546724057?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-28 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546724057","market":"nz","top_or_hot":-1,"title":"Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest <a href=\"https://laohu8.com/S/EOI\">$(EOI)$</a> from AstraZeneca plc, indicating their intent to join the <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043988) on June 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-28 06:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest <a href=\"https://laohu8.com/S/EOI\">$(EOI)$</a> from AstraZeneca plc, indicating their intent to join the <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043988) on June 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0757432116.USD","symbol_name":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDLCnKMT:1","article_id":"2546724057","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546724057","pubTimestamp":1751061617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest  from AstraZeneca plc, indicating their intent to join the Predictive Oncology Outcomes using Multimodal AI  Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellige","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0757432116.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0526926950.USD":"贝莱德欧洲基金","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0171293334.USD":"贝莱德英国基金A2","LU1078025761.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USDHDG) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","03165":"华夏欧优股对冲","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1153584641.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USDHDG) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4082":"医疗保健设备","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU0882574055.USD":"富达全球健康医疗A ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0499090636.EUR":"AZ FUND 1 DIVIDEND PREMIUM \"A-AZ\" ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","LU0969580561.USD":"贝莱德欧洲特别时机基金A2","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0047473722.SGD":"HSBC GIF EUROPE VALUE \"PD\" (SGD) INC","AZN.UK":"阿斯利康制药","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0640478417.SGD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AGH\" (SGDHDG) ACC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD"},"translate_title":"Onco-Innovations Ltd.子公司Inka Health欢迎阿斯利康在AI-Oncology联盟中担任创始角色","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"POAI":0.9,"AZN.UK":0.9},"content_text":"Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium\n    \n\n        Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest $(EOI)$ from AstraZeneca plc, indicating their intent to join the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043988) on June 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}